Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zinc Supplementation in Compensated Advanced Chronic Liver Disease
NCT06434753Phase 3Recruiting
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Oct 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zinc acexamate in chronic liver disease (CLD), sponsored by Vall d'Hebron Research Institute. Started Oct 2022; status: recruiting.
02
Drugs
zinc acexamate
03
Conditions
chronic liver disease (CLD)
Beyond the preview
Go deeper on NCT06434753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434753.